What’s New PsA? (4.3.2026) Save

Dr. Jack Cush reviews the news and major articles from this week, including FDA safety warnings, reports from AAD, PsA trials.

1. Retrospective study of 1st SLE pregnancies from LUNA Registry. Fetal loss was associated w/ aPL (OR 2.46) & pulse steroids (2.46), but not w/ SSA Abs (1.32). 247 pregs, 194 live births, 53 fetal loss. Ro+ vs Ro- no difference in live births or preterm births https://buff.ly/cRKP8al
2. 5 Retrospective cohorts of PM/DM pts showed IIM (myositis) had signif higher risks of IIM patients HTN w/ pregnancy (OR 2.73), & C-section (OR 2.03). Also more preterm birth (3.7), SGA/IUGR (1.9) https://buff.ly/1FkQsFx
3. AFFINITY Study - Combination Biologic Therapy in PsA A pilot trial assessed the efficacy and safety of the guselkumab+golimumab (COMBO) combination versus GUS monotherapy in active PsA (failing a prior tumor necrosis factor inhibitor (TNFi-IR) and showed superiority in ACR 50 https://t.co/f2CB8FnZMB
4. AXIS is an Intl prospective study of 409 psoriatic arthritis pts - found Axial involvement in 27.4% of pts. Axial PsA signif younger (45 vs 47.6 yrs) , male (56% vs 51.5%), more B27 positivity (22% vs 11%), inflammatory back pain (75% vs 43%), & ^CRP (53% vs 37%) https://t.co/XY5pf4BNNm
5. Psychiatrists have the highest Medicare opt-out rate (8% vs 1.2% MDs vs <3% Rheum), leading to a critical shortage of psychiatrists and more antipsychotic management to APRNs and PAs over the last decade. APPs Handle 40% of Antipsychotic Scripts https://t.co/wWnFcnXpRa
6. Time to pregnancy (TTP) in 2 RA cohorts: PARA (n 245, 2002-10) vs PreCARA (n 215, 2011-23), latter Rx by T2T. Median TTP was 251d vs 91d (p<0·0001). Preg w/in 1 yrs was 42% v 77%. 61% PreCARA in remission https://t.co/qIHwXvfzMy
7. Target trial emulation: biologics or JAK vs RTX in RA-ILD -- abatacept (n=694), JAKi (156), IL-6i (389), or TNFi (734), PS-matched =# RTX; no significant differences (HR 0.74-1.09 NS) in outcomes of resp hosp, lung transplant & death. But ABA (HR 0.84) & JAKi (HR 0.62) had less death vs RTX https://t.co/2ZVyf8neVH
8. AAD 2026 Annual Mtg presents new data on another TYK2 inhibitor. In 2 phase 3 RCTs (ONWARD1 ONWARD2) envudeucitinib was superior to placebo & apremilast in 1700 plaque psoriasis pts https://t.co/DPlzDw5m7N
9. Ixekizumab With Tirzepatide Efficacy in Obese Psoriatic Arthritis
10. Brepocitinib in Dermatomyositis
11. FDA Safety Warning: Avacopan and Serious Liver Injury